These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36016109)

  • 41. Can reactogenicity predict immunogenicity after COVID-19 vaccination?
    Hwang YH; Song KH; Choi Y; Go S; Choi SJ; Jung J; Kang CK; Choe PG; Kim NJ; Park WB; Oh MD
    Korean J Intern Med; 2021 Nov; 36(6):1486-1491. PubMed ID: 34038996
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Maternal and Neonatal SARS-CoV-2 Immunoglobulin G Antibody Levels at Delivery After Receipt of the BNT162b2 Messenger RNA COVID-19 Vaccine During the Second Trimester of Pregnancy.
    Kugelman N; Nahshon C; Shaked-Mishan P; Cohen N; Sher ML; Gruber M; Marom I; Zolotarevsky A; Lavie O; Damti A; Zilberlicht A; Bardicef M; Kedar R
    JAMA Pediatr; 2022 Mar; 176(3):290-295. PubMed ID: 34932066
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of gender, age and vaccine on reactogenicity and incapacity to work after COVID-19 vaccination: a survey among health care workers.
    Nachtigall I; Bonsignore M; Hohenstein S; Bollmann A; Günther R; Kodde C; Englisch M; Ahmad-Nejad P; Schröder A; Glenz C; Kuhlen R; Thürmann P; Meier-Hellmann A
    BMC Infect Dis; 2022 Mar; 22(1):291. PubMed ID: 35346089
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Demographic and Clinical Factors Associated With Anti-SARS-CoV-2 Antibody Levels After 2 BNT162b2 mRNA Vaccine Doses.
    Nam SY; Jeon SW; Lee HS; Lim HJ; Lee DW; Yoo SS
    JAMA Netw Open; 2022 May; 5(5):e2212996. PubMed ID: 35587345
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Increased Mild Vaccine-Related Side Effects and Higher Specific Antibody Titers in Health Care Workers with Previous SARS-CoV-2 Infection after the mRNA BNT162b2 Vaccine.
    Ferrari L; Compagno M; Campogiani L; Teti E; Mulas T; Checchi D; Alessio G; Caldara F; Coppola L; De Simone G; Ceccarelli L; Spalliera I; Vitale P; Grelli S; Andreoni M; Sarmati L; Iannetta M
    Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016128
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reactogenicity, immunogenicity, and humoral immune response dynamics after the third dose of heterologous COVID-19 vaccines in participants fully vaccinated with inactivated vaccine.
    Tawinprai K; Siripongboonsitti T; Porntharukchareon T; Wittayasak K; Thonwirak N; Soonklang K; Sornsamdang G; Auewarakul C; Mahanonda N
    Expert Rev Vaccines; 2022 Dec; 21(12):1873-1881. PubMed ID: 35792752
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reduced Titers of Circulating Anti-SARS-CoV-2 Antibodies and Risk of COVID-19 Infection in Healthcare Workers during the Nine Months after Immunization with the BNT162b2 mRNA Vaccine.
    Coppeta L; Ferrari C; Somma G; Mazza A; D'Ancona U; Marcuccilli F; Grelli S; Aurilio MT; Pietroiusti A; Magrini A; Rizza S
    Vaccines (Basel); 2022 Jan; 10(2):. PubMed ID: 35214600
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reactogenicity among health care workers following a BNT162b2 or mRNA-1273 second dose after priming with a ChAdOx1 nCOV-19 vaccine.
    Baldolli A; Fournier A; Verdon R; Michon J
    Clin Microbiol Infect; 2022 Jun; 28(6):885.e1-885.e5. PubMed ID: 35182759
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Depressive symptoms predict antibody titers after a second dose of the SARS-CoV-2 BNT162b2 vaccine among hospital workers in Japan.
    Kaneko H; Tsuboi H
    Brain Behav Immun; 2023 Jan; 107():414-418. PubMed ID: 36116693
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of Age and Sex on Antibody Response Following the Second Dose of COVID-19 BNT162b2 mRNA Vaccine in Greek Healthcare Workers.
    Vassilaki N; Gargalionis AN; Bletsa A; Papamichalopoulos N; Kontou E; Gkika M; Patas K; Theodoridis D; Manolis I; Ioannidis A; Milona RS; Tsirogianni A; Angelakis E; Chatzipanagiotou S
    Microorganisms; 2021 Aug; 9(8):. PubMed ID: 34442806
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety of COVID-19 vaccines in pregnancy: a Canadian National Vaccine Safety (CANVAS) network cohort study.
    Sadarangani M; Soe P; Shulha HP; Valiquette L; Vanderkooi OG; Kellner JD; Muller MP; Top KA; Isenor JE; McGeer A; Irvine M; De Serres G; Marty K; Bettinger JA;
    Lancet Infect Dis; 2022 Nov; 22(11):1553-1564. PubMed ID: 35964614
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reactogenicity after the first and second doses of BNT162b2 mRNA coronavirus disease vaccine: a single-center study.
    Kang YM; Lim J; Choe KW; Lee KD; Jo DH; Kim MJ; Kim JM; Kim KN
    Clin Exp Vaccine Res; 2021 Sep; 10(3):282-289. PubMed ID: 34703812
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers.
    Angel Y; Spitzer A; Henig O; Saiag E; Sprecher E; Padova H; Ben-Ami R
    JAMA; 2021 Jun; 325(24):2457-2465. PubMed ID: 33956048
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reactogenicity following two doses of the BNT162b2 mRNA COVID-19 vaccine: Real-world evidence from healthcare workers in Japan.
    Saita M; Yan Y; Ito K; Sasano H; Seyama K; Naito T
    J Infect Chemother; 2022 Jan; 28(1):116-119. PubMed ID: 34580011
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial.
    Hui AM; Li J; Zhu L; Tang R; Ye H; Lin M; Ge L; Wang X; Peng F; Wu Z; Guo X; Shi Y; Pan H; Zhu J; Song Z; Qiu J; Wang W; Zheng J; Ozhelvaci O; Shpyro S; Bushway M; Derhovanessian E; Kühnle MC; Luxemburger U; Muik A; Shishkova Y; Khondker Z; Hu S; Lagkadinou E; Şahin U; Türeci Ö; Zhu F
    Lancet Reg Health West Pac; 2022 Dec; 29():100586. PubMed ID: 36120090
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antibody Responses to the BNT162b2 mRNA Vaccine in Healthcare Workers in a General Hospital in Japan: A Comparison of Two Assays for Anti-spike Protein Immunoglobulin G.
    Hibino M; Watanabe S; Kamada R; Tobe S; Maeda K; Horiuchi S; Kondo T
    Intern Med; 2022 Mar; 61(6):811-819. PubMed ID: 34980798
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
    Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
    Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
    Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
    Front Immunol; 2021; 12():704773. PubMed ID: 34220867
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series.
    Danese E; Montagnana M; Salvagno GL; Peserico D; Pighi L; De Nitto S; Henry BM; Porru S; Lippi G
    Clin Chem Lab Med; 2021 Aug; 59(9):1585-1591. PubMed ID: 33838087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.